Treatment of chronic experimental *Trypanosoma cruzi* infections in mice with MK-436, a 2-substituted 5-nitroimidazole

S.G. Andrade,¹ R.C. Silva,² & C.M.G. Santiago²

The antiprotozoal drug 3-(1-methyl-5-nitroimidazol-2-yl)-3a, 4,5,6,7,7a-hexahydro-1,2-benzisoxazole (MK-436) is highly efficacious for treating mice chronically infected with different strains of *Trypanosoma cruzi*. The compound was administered by gavage in two daily doses of 250 mg per kg body weight to 130 mice that had been infected for 90 to 400 days with either type II or III strains of *T. cruzi*. The following parasitological cure tests were carried out: xenodiagnosis, haemoculture, and inoculation of blood into newborn mice. Indirect immunofluorescence tests and histopathological studies were also performed.

The results indicate that the drug is highly efficacious against chronic infection caused by both type II (cure rate, 90%) and type III strains (cure rate, 95.7%). Histopathological examinations showed complete clearance of the cardiac and muscular lesions in 36% of the mice infected with type II strains and a decrease in the intensity and extension of the lesions in mice infected with type III strains. Indirect immunofluorescence tests were persistently positive for all the mice 3–6 months after the treatment.

Of the several compounds that are effective in treating the acute phase of experimental infection with *Trypanosoma cruzi* (1–6), some produce high cure rates among mice. However, it has been difficult to evaluate the cure rate of chronic infections since during this phase the level of parasites both in peripheral blood and in cells is low, and the results of indirect immunofluorescence antibody tests (IFAT) may be persistently positive in animals that exhibit parasitological cure (7).

Murray et al. have described the efficacy of two 2-substituted 5-nitroimidazoles (MK-436 and L 634, 549) during the early and late (8 weeks) phase of *T. cruzi* infections (6). Also Andrade et al. have shown that administration of MK-436 to mice acutely infected with different strains of *T. cruzi* results in high cure rates (7). Even those strains that are highly resistant to benzimidazole and nifurtimox (2) are susceptible to MK-436.

We report here the results of an investigation to determine the effectiveness of MK-436 against chronic infection with different strains of *T. cruzi*, as well as the influence of treatment with MK-436 on tissue lesions and on the outcome of serological tests.

Materials and methods

As test animals, 130 chronically infected Swiss mice that had survived virulent infection with *T. cruzi* for 90–400 days were used. The mice had previously been inoculated intraperitoneally with the blood of infected mice that contained 1 × 10⁴ to 5 × 10⁴ blood trypomastigotes from different strains of *T. cruzi* (Table 1). Strains were characterized biologically as type II or type III according to a procedure described by Andrade (8) and following recommendations made by WHO (9). Infection with type II strain results in slowly increasing parasitaemia, with peaks between the 12th and 20th days of infection, predominance of broad parasite forms in circulating blood, and myocardiotropism; on the other hand, infection with type III strain leads to a slower increase in parasitaemia, with peaks around the 20th to 30th days of infection, predominance of broad parasite forms, and an intense skeletal muscle tropism (8).

The mice were divided into the following groups: 80 that received chemotherapy and 50 that remained as untreated controls. Only results from the 67 mice that received treatment and the 47 untreated mice which survived until the end of the experiments and were evaluated parasitologically, serologically, and histopathologically were used (Table 1).

**Treatment**

Mice were administered MK-436 (3-(1-methyl-5-nitroimidazol-2-yl)-3a,4,5,6,7,7a-hexahydro-1,2-benzisoxazole)* (6,7) by gavage in two daily doses of 250 mg

---

¹ Associate Professor, Universidade Federal da Bahia, Centro de Pesquisas Gonçalo Moniz, Rua Valdemar Falcão, 121-Brotas, Salvador, Bahia, Brazil. Requests for reprints should be sent to this address.

² Biologist, Universidade Federal da Bahia, Centro de Pesquisas Gonçalo Moniz, Salvador, Bahia, Brazil.

© World Health Organization 1989
arteriolitis, both in the focal changes with severity inflammatory interstitial, + +, on 510 findings. Histopathological chemotherapy with per kg body weight. The duration of treatment was 30 days for 47 mice and 60 days for 20.

**Evaluation of the results**

Before being killed for histopathological study, parasitological and serological tests were carried out on the mice that were treated with MK-436. Parasitological cure tests, consisting of xenodiagnosis with five 4th–5th stage *Rhodnius prolixus* nymphs, direct examination of peripheral blood, inoculation of 0.1-ml samples of this blood into five newborn mice, and haemoculture, were performed 30–90 days after the treatment. Serological evaluations were carried out using IFAT, as described by Camargo (10), with cultured forms of *T. cruzi* as antigens, serum dilutions from 1:10 to 1:80, and antimal IgG fluorescein conjugate at a dilution of 1:80.

**Results**

The parasitological cure rates and serological responses are shown in Table 1. No significant differences in the proportions of parasitological tests that were negative were detected between mice treated for 30 or 60 days. Cure rates of 90% were achieved for infections with the type II strain and of 95.7% for those with type III strain (Table 1). All of the treated mice had positive IFAT results, with titres that varied from 1:10 to 1:80, as evaluated 3 to 6 months after treatment.

**Histopathological findings**

The severity of myocarditis and myositis was graded on a three-point scale: +, for mild and focal perivascular, interstitial, or subepicardial mononuclear infiltration; + +, for moderate, diffuse, and focal inflammatory lesions, as well as focal destruction of muscle cells; and + + +, for diffuse and severe inflammatory changes with extensive lesions of muscle fibres and dense focal mononuclear infiltration. Necrotizing arteriolitis, both in the skeletal muscle and myocardium, was also detected in various grade categories.

In the untreated control mice, the histopathological lesions ranged from mild and focal (+) to diffuse and severe (++++), as shown in Table 2. Myocardial lesions predominated in infections with type II strain and skeletal muscle involvement with type III. Type III infections exhibited predominantly arteriolar lesions (Fig. 1a–f).

**Table 1: General data on the mice that were chronically infected with different strains of *Trypanosoma cruzi* and given chemotherapy with MK-436**

<table>
<thead>
<tr>
<th>Strain of <em>T. cruzi</em></th>
<th>No. of mice treated</th>
<th>No. of controls</th>
<th>Parasitological cure rate (%)</th>
<th>No. serologically negative by IFAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type II*</td>
<td>44</td>
<td>25</td>
<td>90</td>
<td>0</td>
</tr>
<tr>
<td>Type III*</td>
<td>23</td>
<td>22</td>
<td>95.7</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>67</td>
<td>47</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Strains: 10-Mont, 12-Mont, 15-Mont, 16-Mont, 18-Mont, 20-Mont, 22-Mont, and 24-Mont (Montalvania strains); 02-Coteg. (Cotegipe strain); 05-Mam and 13-Mam (Mambai strains); and 12-SF (São Felipe strain).

* Strains: 13-Mont, 19-Mont (Montalvania strains); Bolivian strain; and Colombian strain.

**Table 2: Distribution of tissue lesions in untreated control mice that were chronically infected with type III strains of *Trypanosoma cruzi***

<table>
<thead>
<tr>
<th>Strain code*</th>
<th>Myocarditis</th>
<th>Myositis</th>
<th>Arteriolitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Col-1</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Col-2</td>
<td>+</td>
<td>+ +</td>
<td>+++</td>
</tr>
<tr>
<td>Col-3</td>
<td>+</td>
<td>+ +</td>
<td>+</td>
</tr>
<tr>
<td>Col-4</td>
<td>+</td>
<td>+ +</td>
<td>+</td>
</tr>
<tr>
<td>Col-5</td>
<td>+</td>
<td>+ +</td>
<td>+</td>
</tr>
<tr>
<td>Col-6</td>
<td>+</td>
<td>+ +</td>
<td>+</td>
</tr>
<tr>
<td>Col-7</td>
<td>+</td>
<td>+ +</td>
<td>+</td>
</tr>
<tr>
<td>Col-8</td>
<td>+</td>
<td>+ +</td>
<td>+</td>
</tr>
<tr>
<td>Col-9</td>
<td>+</td>
<td>+ +</td>
<td>+</td>
</tr>
<tr>
<td>Col-10</td>
<td>+</td>
<td>+ +</td>
<td>+</td>
</tr>
<tr>
<td>Mont-1</td>
<td>+</td>
<td>+ +</td>
<td>+</td>
</tr>
<tr>
<td>Mont-2</td>
<td>+</td>
<td>+ +</td>
<td>+</td>
</tr>
<tr>
<td>Mont-3</td>
<td>+</td>
<td>+ +</td>
<td>+</td>
</tr>
</tbody>
</table>

* ( +): mild and focal perivascular, interstitial, or subepicardial mononuclear infiltration; (+++): moderate, diffuse, and focal inflammatory lesions, as well as focal destruction of muscle cells; (+++): diffuse and severe inflammatory changes with extensive lesions of muscle fibres and dense focal mononuclear infiltration; and (−): no inflammatory lesion.

* Bol-1–9: Bolivian strains; Col-1–10: Colombian strains; and Mont-1 and Mont-2 = 13-Montalvania strain, and Mont-3 = 19-Montalvania strain.
**Treatment of Trypanosoma cruzi infections in mice**

Fig. 1. Histopathological lesions observed in the untreated control mice: (a) and (b) myocardium, showing diffuse infiltration of mononuclear cells; (c) and (d) skeletal muscle, showing destruction of muscle fibres, marked infiltration of focal inflammatory cells, and interstitial fatty infiltration; and (e) and (f) focal necrotizing arteriolitis in the myocardium and skeletal muscle, respectively.

**Treated mice**

Of mice that were infected with type II strains, complete clearance of the cardiac and muscular lesions occurred in 36% (16 out of 44); mild and focal lesions (+) were present in 52% (23 out of 44); moderate alterations (+ +) in 9% (4 out of 44); and necrotizing arteriolitis in 8.6%. All the mice infected with type III strains (Table 3) that were treated exhibited mild (59%) or moderate lesions (41%), while mild to moderate necrotizing arteriolitis was detected in 22% of such mice (Fig. 2a–c). All the mice infected with type II strains without cardiac or skeletal muscle lesions were parasitologically negative.

As shown in Table 3, the persistence of inflammatory lesions in the myocardium or in skeletal muscle was most prominent in the mice infected with type III strains; such lesions were mild to moderate,
Table 3: Frequency of histopathological lesions of the myocardium and skeletal muscle in mice that were chronically infected with Trypanosoma cruzi and treated with MK-436, compared with untreated infected controls

<table>
<thead>
<tr>
<th>Grade of lesion</th>
<th>Infection with type II strain</th>
<th>Infection with type III strain</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Untreated controls (%)</td>
<td>Treated mice (%)</td>
</tr>
<tr>
<td>+</td>
<td>46.0</td>
<td>52.0</td>
</tr>
<tr>
<td>+ +</td>
<td>38.4</td>
<td>9.0</td>
</tr>
<tr>
<td>+ + +</td>
<td>15.4</td>
<td>0.0</td>
</tr>
<tr>
<td>Necrotizing arteriolitis</td>
<td>46.0</td>
<td>8.6</td>
</tr>
<tr>
<td>No lesions</td>
<td>0</td>
<td>36.0</td>
</tr>
</tbody>
</table>

* For explanation, see footnote a, Table 2.

Comments

The results reported here confirm the curative efficacy of MK-436 against experimental T. cruzi infections (9), even for those in the chronic phase. Parasitological cure rates were high, both for infections with type II (90%) and type III strains (95.7%). It should be noted that strains characterized biologically as type III were highly resistant to treatment with either benznidazole or nifurtimox during the acute phase of infection (2). All treated and parasitologically cured mice exhibited persistently positive IFAT results. As previously suggested (2,9), negative parasitological tests are the most acceptable cure criterion. However, Cançado has postulated that only negative results in serological tests provide evidence of cure from Chagas disease after chemotherapy (11). For example, among chronic human cases of Chagas disease that were treated either with benznidazole or nifurtimox, Cançado reported cure rates that were very low or zero with persistently positive serological tests (11). However, follow-up studies on some of the treated patients surprisingly found that they were serologically negative 5 years after treatment. Both the data we have reported here and the above-mentioned clinical results (11) indicate that positive post-treatment serological tests may be transient and dependent on the presence of residual antigenic stimulation. To investigate this further, we immunolabelled specific T. cruzi antigens with peroxidase and demonstrated by immunoelectronmicroscopy that it binds to the dendritic cells of the spleen (12). The results were positive 3 to 6 months after treatment for mice that were parasitologically cured and that had positive IFAT results. The index of cure, obtained independently of negative serological tests, therefore indicates that chronic T. cruzi infections can be cured by chemotherapy with MK-436.

The importance of these observations is empha-
sized by the fact that histopathological lesions in untreated controls totally or partly subsided in a significant proportion of mice that were treated with MK-436. A similar regression has previously been described by Andrade & Andrade for nifurtimox. (13)

Although mild-to-moderate inflammatory lesions occurred in some treated and apparently cured mice, mainly those infected with type III strains of T. cruzi, they were never severe. The presence of persistent necrotizing arteriolitis in treated mice, a frequent finding in those that are chronically infected with T. cruzi (13, 14), has been interpreted as evidence for the presence of circulating immunocomplexes, probably caused by prolonged antigenic stimulation.

In Chagas disease delayed-type hypersensitivity mechanisms are involved in the development of chronic inflammatory lesions (15). In view of the results of the present investigation, such mechanisms are apparently correlated with patent parasitism, since parasitological cure may determine clearance of inflammatory lesions or its partial regression. This inflammatory process in infected and untreated mice (12) appears as a diffuse and focal mononuclear infiltration, with predominance of macrophages, as confirmed by electronmicroscopy (14), and is associated with active fibrosis, a typical feature of chronic Chagas disease myocarditis. In delayed-type hypersensitivity, enhanced collagen synthesis is observed (16). It is therefore important that parasitological cure of a proportion of chronically infected mice also causes histopathological lesions to regress or disappear, even when serological tests are persistently positive.

Acknowledgements

This investigation was supported financially by the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases and by the National Council for Scientific and Technological Development (CNPq), Brazil. Merck, Sharp & Dohme Research Laboratories, Rahway, NJ, USA, are thanked for supplying samples of MK-436.

Résumé

Traitement des infections expérimentales chroniques à Trypanosoma cruzi chez la souris avec le MK-436, un dérivé du nitro-5 imidazole

Le traitement des infections à Trypanosoma cruzi en phase chronique présente des difficultés et les données disponibles sont rares et se prêtent mal à l'évaluation. Certains composés ont fait la preuve de leur efficacité antiparasitaire dans la phase aiguë de la maladie, que ce soit chez l'homme ou chez l'animal d'expérience. Parmi ceux-ci, le MK-
436 (un nitro-5 imidazole substitué en position 2) qui n’a fait l’objet jusqu’ici que d’essais expérimentaux, a un effet trypanosomicide certain in vivo et il donne un taux de guérison élevé chez les souris présentant une infection aiguë à T. cruzi. L’étude décrite ici a permis de vérifier expérimentalement l’efficacité de cette substance dans la phase chronique de l’infection chez la souris et d’évaluer son effet sur les lésions histopathologiques.

Dans cette étude, 130 souris présentant une infection chronique à T. cruzi ont été traitées avec le MK-436. L’infection durait depuis 90 à 400 jours et avait été provoquée par l’inoculation de 1 x 10⁴ à 5 x 10⁴ trypomastigotes sanguins. Les souches de T. cruzi ayant servi à infecter les souris avaient été précédemment identifiées comme appartenant au type II ou au type III, d’après leurs caractéristiques biologiques. Le médicament a été administré par gavage en deux doses journalières de 250 mg/kg de poids corporel. Les résultats ont été évalués par des épreuves parasitologiques (xénodiagnostic, inoculation secondaire à des souris nouveau-nées et hémoculture), ainsi que par des épreuves d’immuno-fluorescence indirecte et par des examens histopathologiques.

Le taux de guérison parasitologique a été de 90% chez les souris infectées avec la souche de type II et de 95,7% chez celles infectées avec la souche de type III. Les résultats des épreuves d’immuno-fluorescence indirecte étaient encore positifs 3 à 6 mois après le traitement. Par comparaison avec les témoins non traités, les lésions histopathologiques ont complètement disparu après traitement chez 36% des souris infectées avec la souche de type II. Des lésions histopathologiques de gravité faible à modérée, notamment des infiltrations du myocarde et des muscles squelettiques ainsi qu’une artérioïde nécrosante ont persisté chez certains animaux traités, surtout parmi ceux qui avaient été infectés avec la souche de type III.

Cette étude montre qu’un traitement par le MK-436 peut amener la guérison parasitologique et la régression des lésions cardiaques chez des souris présentant une infection chronique à T. cruzi.

References


